Despite recent advances in medical research, the incidence of diabetes and cardiovascular
disease (CVD)-induced fatal events is increasing. The literature point towards several co-occurring
pathways that could lead to terminal complications related with these diseases. Different pathophysiological
alterations such as hyperglycaemia, hyperinsulinaemia, insulin resistance, obesity, endothelial
dysfunction and oxidative stress lead to the initiation and progression of atherosclerotic plaques. In view
of the continuous rise in fatal events and overlapping pathological conditions associated with CVD and
diabetes, there is a critical need to develop a common treatments against these diseases. The present
review highlights the possible use of common drugs that could target diabetes and associated CVD.